Molecular alterations in apoptotic pathways after PKB/Akt-mediated chemoresistance in NCI H460 cells

S Hövelmann¹,², TL Beckers¹,³ and M Schmidt*¹,³
¹ASTA Medica Oncology, Weismüllerstr. 45, D-60314 Frankfurt, Germany
²RDR/B4, Oncology Research, Byk-Gulden-Str. 2, D-78467 Konstanz, Germany
³Beckers’ and Schmidt’s Current address: Altana Pharma AG, Dept. RDR/B4, Oncology Research, Byk-Gulden-Str. 2, D-78467 Konstanz, Germany

Protein kinase B/Akt has been described as a central mediator of antiapoptotic signals in cancer cells. Furthermore, Akt has been shown to affect cell cycle progression and proliferative pathways and to possess a potential function in tumorigenesis and chemoresistance. In this study, we show that the ectopic expression of a constitutively active form of Akt1 (CA-Akt1) results in enhanced chemoresistance of NCI H460 human NSCLC cells towards a panel of chemotherapeutic agents. To understand the molecular alterations leading to impaired chemosensitivity mediated by activated Akt, we analysed various apoptotic pathways, including the activation of p53, caspases 3, 7, 8, and 9, release of cytochrome c from mitochondria, and the expression levels of pro- and antiapoptotic proteins such as Bcl-2, Bcl-xL, Bcl-xS, Bax, or Bfl-1. We observed that expression of CA-Akt did not interfere with single defined apoptotic switches, but modulated the apoptotic threshold of several apoptotic pathways towards increasing the threshold of onset. In particular, we found that CA-Akt-expressing cells displayed increased expression of the antiapoptotic Bcl-2 family member protein Bcl-xL and a delayed onset of the p53 pathway after treatment with cisplatin or Mitoxantrone. Thus, our data suggest that Akt mediates chemoresistance in NCI H460 cells by interfering with and delaying the onset of various apoptotic pathways. A complete inactivation of apoptotic pathways was observed in none of the molecular alterations investigated. Our data strengthen the role of Akt as a central mediator of cell survival signals and/or chemoresistance and as an attractive target for cancer cell chemosensitisation.

British Journal of Cancer (2004) 90, 2370–2377. doi:10.1038/sj.bjc.6601876 www.bjcancer.com Published online 11 May 2004 © 2004 Cancer Research UK

Keywords: protein kinase B/Akt; apoptosis; chemoresistance

The process of malignant transformation requires cells to undergo a variety of molecular alterations to acquire growth properties that allow them to divide indefinitely and in an uncontrolled fashion under conditions of low oxygen and poor nutrient supply. Such conditions would normally induce programmed cell death, and malignant cells additionally have to acquire molecular mechanisms to evade apoptotic stimuli in order to survive and to form solid tumours. It is conceivable that antiapoptotic signalling cascades play an equally important role in the development of the pathological cancer phenotype as the dysregulation of proliferative signalling cascades.

Phosphatidylinositol 3-kinase (PI3 K), which relays various signalling pathways via the production of phosphatidylinositol lipids, has been identified as a central mediator of cell growth, metabolism, migration, and survival (reviewed in Wymann et al., 2003). PI3 K regulates cellular functions by recruiting PI(3, 4, 5)P₃ binding proteins to the plasma membrane preferentially via pH domains. The prototype of these molecules is protein kinase B/Akt. Binding to PI(3, 4, 5)P₃ results in a conformational change which makes Akt susceptible to phosphorylation at threonine 308 and serine 473 (Alessi and Cohen, 1998). Phosphorylation of Akt results in its activation and dissociation from the membrane. The resolution of the crystal structures of activated Akt and inactive Akt2 has provided further clues about their regulation and activation (Yang et al., 2002; Huang et al., 2003). Substrates of Akt are phosphorylated within the consensus sequence RXRXXS/T (Obata et al., 2000). Several target proteins of Akt involved in antiapoptotic signalling, the regulation of the cell cycle, and insulin homeostasis have been described.

GSK3 was the first protein known to be inactivated by Akt via phosphorylation at serine 9 (Cross et al., 1995). Besides the regulation of glycogen synthesis, GSK3 regulates several intracellular signalling pathways including AP1 (Scala et al., 2001), CREB (Cross et al., 1995), and the tumour-suppressor gene product APC (Zumbrunn et al., 2001). Akt can promote cellular survival by inhibiting proteins involved in the regulation of apoptosis. One such mechanism is the phosphorylation of the proapoptotic protein Bad at serine 136 by Akt, which creates a binding site for 14-3-3 proteins and thereby prevents Bad from binding and inhibiting the antiapoptotic protein Bcl-xL (Datta et al., 1997). Another direct mechanism is the Akt-mediated phosphorylation of caspase 9 at serine 196 inhibiting its protease- and apoptosis-initiating activity (Cardone et al., 1998). c-FLIP, a...
dominant-negative homologue of caspase 8, is upregulated in tumour cell lines on a transcriptional level by the Akt pathway through a yet unknown mechanism (Panka et al., 2001). The apoptosis signal-regulating kinase 1 (Ask1) is phosphorylated by Akt at serine 83, leading to its inhibition and a reduced activation of JNK, which under certain circumstances can promote apoptosis (Kim et al., 2001). The forkhead transcription factor FKHL1 is phosphorylated by Akt at threonine 32 and serine 253, resulting in its retention in the cytoplasm by 14-3-3 proteins. Thus, FKHL1-mediated transcription of proapoptotic proteins such as the Fas ligand is reduced and cell survival is promoted (Brunet et al., 1999).

Other substrates of Akt include phosphofructokinase 2 (Deprez et al., 1997), Iκ-B kinase from the NF-κB pathway (Ozes et al., 1997), and endothelial NO synthase (Dimmel et al., 1999).

Akt can influence proliferative and cell cycle regulatory pathways and thereby indirectly modulate tumour chemosensitivity by the regulation of Cyclin D stability (Muise-Helmericks et al., 1998) and inhibition of p27kip1 protein levels (Collado et al., 2000). Furthermore, Akt has been shown to directly phosphorylate the cyclin-dependent kinase inhibitors p21<sup>WAF1</sup> at threonine 145 and serine 146 (Zhou et al., 2001) and p27<sup>kip1</sup> at threonine 157 (Liang et al., 2002), leading to their cytosolic retention and neutralisation of their growth-inhibitory effect. In addition, cytoplasmic p21<sup>WAF1</sup> binds to ASK1-inhibiting apoptosis (Asada et al., 1999). The p53 pathway is influenced by Akt through phosphorylation of the p53-regulating protein MDM2 at residues serine 166 and 186 (Mayo and Donner, 2001). Akt-mediated phosphorylation of MDM2 results in the translocation of MDM2 from the cytoplasm into the nucleus, leading to reduced cellular p53 protein levels and decreased p53 transcriptional activity.

Since PKB/Akt is involved in such a multitude of apoptosis regulatory pathways, it is not surprising that Akt is overexpressed in a variety of human tumour cell lines and cancers (Bellacosa et al., 1999; Ringel et al., 2001; Roy et al., 2002) and a mediator of oestrogen resistance in breast cancer cells (Campbell et al., 2001). Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that regulates Akt activity in cancers can either be deregu...
Akt kinase assay

The Akt kinase assay was performed using the Akt Kinase Assay Kit from Cell Signalling Technology, Inc. with GSK-3 fusion protein as substrate. Cells were seeded out in 10-cm dishes and switched to medium containing 0.5% serum after attachment. After starvation overnight, cells were either kept unstimulated or were stimulated for 20 min with medium containing 10% FCS supplemented with a cocktail containing each 10 ng ml^{-1} of EGF, PDGF, and IGF-1. Cells were lysed and lysates clarified by centrifugation. Supernatants were swirled for 3 h at 4°C with an anti-Akt-agarose conjugate. After three times washing with lysis buffer and with kinase buffer, the immunoprecipitates were subjected to an in vitro kinase reaction with 40 μl of reaction mixture containing kinase reaction buffer supplemented with 200 μM ATP and 1 μg GSK-3 fusion protein. The reaction was allowed to process at 30°C for 30 min and stopped by boiling the samples in SDS sample buffer for 5 min. Immunoprecipitates were separated by 12.5% SDS–PAGE and then analysed in immunoblot assays with antibodies specific for phospho-GSK (Ser 21/9) and Akt. Signals were visualised with the ECL chemoluminescence detection kit (Amersham-Braunschweig, Germany).

Colorimetric detection of caspase activation

The activation of the initiator caspases 8 and 9, as well as the effector caspase 3, was determined by in vitro assays with cell lysates using the caspase 3 cellular activity assay kit, the caspase 8 assay kit (both Calbiochem-Novabiochem, San Diego, CA, USA), and the caspase 9 colorimetric assay kit (R&D Systems, Minneapolis, MN, USA). Cells were seeded out in 10-cm dishes and switched to medium containing 0.5% serum after attachment. After starvation overnight, cells were treated with 400 mM Mitoxantrone or 20 μM cisplatin for 24 and 36 h, respectively. Cells were lysed and lysates were clarified by centrifugation. Supernatants were subjected to caspase activity assays according to the manufacturer’s recommendations with specific peptide substrates (DEVD-pNA for caspase 3, Ac-IETD-pNA for caspase 8, and LEHD-pNA for caspase 9). Active caspases lead to the proteolytic cleavage of the peptide substrates and thereby the release of p-nitroanilin, which was quantified with the Victor Multilabel Counter at a wave length of 405 nm.

Fractional centrifugation and cytochrome c ELISA

For analysing the distribution of cytochrome c between mitochondria and cytosol cells were fractionally centrifuged and a cytochrome c ELISA (EMD Biosciences, Inc., San Diego, CA, USA) was performed. Cells were seeded out in 10-cm dishes and switched to medium containing 0.5% serum after attachment. After starvation overnight, cells were treated with 400 mM Mitoxantrone or 20 μM cisplatin for 8 h. After treatment, cells were removed from the dish, resuspended in buffer A (20 mM Hepes-KOH, pH 7.5, 10 mM KCl, 1.5 mM MgCl₂, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 250 mM sucrose, and protease inhibitors), and homogenised using a teflon homogeniser. The homogenate was centrifuged to remove cellular debris (2000 g/10 min). The supernatant was again centrifugated (12500 g/30 min) and 500 μl solubilisation buffer (from caspase 9 colorimetric assay kit) was added to the supernatant representing the cytosolic fraction. The pellet was resuspended in 500 μl buffer B (250 μl buffer A plus 250 μl solubilisation buffer) representing the mitochondrial fraction. Both fractions were subjected to cytochrome c ELISA assays according to the manufacturer’s specifications. For each sample, the relative distribution of cytochrome c between cytosolic and mitochondrial fraction was calculated.

RESULTS

Ectopic expression of farnesylated Akt1 mediates chemoresistance in NCI H460 human lung cancer cells

To establish a cellular system that allows to analyse mechanisms of chemoresistance directly related to Akt, we stably transfected NCI H460 human NSCLC cells with an expression vector for constitutively active Akt. This plasmid encoded for Akt1 devoid of its N-terminal PH domain (replaced by a FLAG tag for antibody detection). To target Akt1 to the membrane for constitutive activation, we inserted a C-terminal sequence tag encoding a farnesylation motif and a stretch of basic amino acids (Schmidt et al, 2002).

Single-cell clones were analysed for ectopic expression of Akt1 by immunoblot analysis of cell lysates with an M2 anti-FLAG antibody, and positive clones (NCI H460-Akt1) were used in this study. To assess whether ectopically expressed farnesylated Akt1 was phosphorylated at threonine 308 and serine 473, selected clones were analysed in immunoblots for their phosphorylation status at these residues (Figure 1). NCI H460-Akt1 cells were starved for 16 h and then stimulated with medium containing 10% serum or 10% serum plus growth factors (EGF, PDGF, and IGF-1). Cells were transfected with the empty vector were used as controls. The results are shown in Figure 1A: endogenous Akt1 was detected as a protein migrating at an M₆ around 66 kDa, whereas ectopically expressed CA-Akt1 was detected with both, anti-Akt1 and anti-FLAG antibodies as a protein with an M₆ of about 50 kDa (due to the lack of the PH domain). Phosphorylation of endogenous Akt1 at Ser473 was induced by stimulation of cells with a growth factor cocktail, and, to a lesser extent, by stimulation with serum alone, while phosphorylation at Thr308 was hardly detectable. In contrast, farnesylated Akt1 was phosphorylated at both residues irrespective of serum conditions or growth factor stimulation.

To determine the kinase activity of endogenous and ectopically expressed farnesylated Akt1, an in vitro kinase assay with immunoprecipitated Akt from cell lysates and GSK-3 fusion protein as substrate was performed under conditions as described for Figure 1A (for details, see Materials and methods). As shown in Figure 1B, endogenous Akt1 in control cells exhibited no detectable kinase activity after serum deprivation, but stimulation with serum and growth factors strongly induced kinase activity. In immunoprecipitates from NCI H460-Akt1 cells, kinase activity from ectopically expressed Akt1 could already be detected under serum-free conditions. Upon serum and growth factor stimulation, Akt kinase activity was induced to a much greater extent as in control cells. The results from the in vitro kinase assay and from the immunoblot analysis of Akt1 phosphorylation status show that ectopically expressed farnesylated Akt1 is constitutively activated in human NCI H460-Akt1 cells and that these cells display a higher Akt kinase activity than control cells irrespective of medium conditions. Surprisingly, we observed that CA-Akt1 transfected clones displayed a slight growth retardation compared to control transfected cells (Figure 1C). Analysis of the expression levels for the cell cycle inhibitors p21^{Waf1} and p27^{Kip1}, respectively, revealed no change in protein abundance. However, we observed a reduced electrophoretic mobility of p21^{Waf1} in NCI H460-Akt1 cells, which might be indicative of increased p21^{Waf1} phosphorylation (Figure 1D).

To assess whether the ectopic expression of CA-Akt1 modulates the cellular response to treatment with chemotherapeutic regimen, we compared the sensitivity of control transfected human NCI H460 cells with the sensitivity of NCI H460-Akt1 cells towards a panel of chemotherapeutics, namely cisplatin, Mitoxantrone, 5-fluorouracil, doxorubicin, and paclitaxel. The viability of the cells after incubation with the substances for 72 h was determined with a standard XTT assay as described in Materials and methods. The most striking differences were observed with the DNA alkylating...
PKB/Akt-mediated chemoresistance in NCI H460 cells
S Høvelmann et al

Figure 2. Decreased chemosensitivity of NCI H460-Akt1 cells towards doxorubicin, cisplatin, and Mitoxantrone. Control transfected NCI H460 cells (filled squares) or NCI H460-Akt1 cells (open triangles) were seeded in 96-well plates in medium containing 0.5% serum. After 24 h cells were treated with different concentrations of doxorubicin, cisplatin, or Mitoxantrone as indicated and incubated for another 72 h at 37°C. Cell viability was then determined with a standard XTT assay as described in ‘Materials and methods’. Values are the mean of at least three independent experiments.

Table 1. Chemosensitivity of control transfected NCI H460 cells or NCI H460-Akt1 cells

| Compound   | IC50 (μM) (Control) | IC50 (μM) (Akt1) | Resistance factor |
|------------|---------------------|------------------|-----------------|
| 5-FU       | 0.03                | 0.09             | 3               |
| Cisplatin  | 0.6                 | 5.6              | 9.3             |
| Doxorubicin| 0.055               | 0.78             | 14              |
| Paclitaxel | 0.002               | 0.005            | 2.5             |
| Mitoxantrone| 0.005              | 0.1              | 20              |

Values were determined as average from at least three independent experiments performed as quadruplicates. The resistance factor was calculated as the IC50 value of NCI H460-Akt1 cells divided by the IC50 value of control transfected NCI H460 cells.

fluorouracil (2.5- and 3-fold decrease, respectively) which primarily acts in the S-phase of the cell cycle. The IC50 values towards the various chemotherapeutics are summarised in Table 1. Importantly, the differential chemoresistance was only detected when cells were grown in low serum. If cells were cultured under normal medium conditions, the activation of endogenous Akt through serum components probably suffices to activate Akt-dependent antiapoptotic pathways. These data suggest that the expression of activated Akt1 in human NCI H460 NSCLC cells can desensitise this cell line especially towards DNA reactive chemotherapeutics, but – at least in our system – does hardly alter the sensitivity towards cell cycle specific agents such as paclitaxel.

Modulation of apoptotic pathways by CA-Akt1 after chemotherapeutic treatment of NCI H460 lung cancer cells

Most of the chemotherapeutics kill tumour cells via the induction of apoptosis (Kaufmann and Earnshaw, 2000). To understand the molecular alterations that lead to decreased chemosensitivity of NCI H460-Akt1, we examined several apoptotic pathways and executors and focused our analyses on cisplatin- and Mitoxantrone-induced cell death, which were found to be most strongly influenced by CA-Akt1.

A very sensitive cell death ELISA detecting histone-associated DNA fragments was initially employed to determine the time...
Molecular and Cellular Pathology
PKB/Akt-mediated chemoresistance in NCI H460 cells
S Hövelmann et al

Points and concentrations of chemotherapeutics at which apoptosis is already initiated in control cells but not yet visible by DNA fragmentation in CA-Akt1-transfected cells. The optimal time points and concentrations were found to be 20 μM cisplatin (incubation time 36 h) and doses between 150 and 400 nM Mitoxantrone (incubation time 24 h) (data not shown). Further experiments were conducted using these compounds at the indicated concentrations.

The activation of certain caspases is indicative of specific pathways that are activated in order to execute apoptotic stimuli (e.g. death receptor-mediated activation of caspases 8 and 10 or activation of caspase 9 by the apoptosome (Peter and Krammer, 1998; Zou et al, 1999). Upon induction of caspase cascades, a subset of cellular caspase downstream target proteins are proteolytically cleaved. Poly-ADP-ribose polymerase (PARP), one such target protein, is one of the earliest proteins targeted for a specific cleavage to a 89-kDa C-terminal fragment with a reduced catalytic activity and a 24 kDa N-terminal peptide, which retains the DNA-binding domains during the initiation of apoptosis (Peter and Krammer, 1998).

For the initial examination of caspase activation in Akt-mediated chemoresistance, we treated NCI H460-Akt1 cells and control cells with 20 μM cisplatin for 36 h. Subsequently, immunoblots with antibodies specific for proteolytic cleavage of initiator and effector caspases as well as the DNA repair enzyme PARP were performed.

Control cells treated with cisplatin showed activation of initiator caspases 8 and 9, effector caspases 3 and 7 as well as the caspase target PARP (Figure 3A and B, left panels). In contrast, cleavage of caspases 8, 9, and 7 in NCI H460-Akt1 cells was greatly diminished, while no cleavage of caspase 3 and PARP was observed at these time points (Figure 3A and B, right panels). Overall, caspase activation upon treatment with Mitoxantrone (150 nM for 24 h) was much weaker as compared to treatment with cisplatin (data not shown).

Colorimetric caspase activity assays were conducted in order to further substantiate the observation of differential caspase activation in CA-Akt1 transfected NCI H460 cells. After incubation with either Mitoxantrone (400 nM; 24 h incubation time) or cisplatin (20 μM; 36 h incubation time), lysates from control cells exhibited a significantly stronger caspase 3 and 9 activity compared to cells expressing constitutively activated Akt1 (Figure 3C). Caspase 8 activity was induced to 5.3 pmol min⁻¹ in control cells after cisplatin treatment compared to 1.4 pmol min⁻¹ in untreated cells. No increase in caspase 8 activity was detected for NCI H460-Akt1 cells incubated with cisplatin. Treatment with Mitoxantrone led to a slight but statistically not significant induction of caspase 8 activity in both control and NCI H460-Akt1 cells. Taken together, activation of both, initiator and effector caspases, is quantitatively reduced and kinetically delayed in NCI H460-Akt1 cells. However, no general qualitative differences were observed, indicating that ectopic expression of CA-Akt1 is only capable of delaying certain apoptotic pathways, but not of completely suppressing the activity of specified caspases.

It has been described that activated Akt1 can influence the onset of apoptosis by interfering with proteins from the mitochondrial pathway of apoptosis (Datta et al, 1997; Pugazhenthi et al, 2000). Furthermore, the induction of apoptosis by chemotherapy in NCI H460 cells has been shown to be dependent on a functional mitochondrial pathway (Ferreira et al, 2000). The initial step is the release of cytochrome c from mitochondria. Therefore, lysates from control and NCI H460-Akt1 cells treated with 400 nM Mitoxantrone or 20 μM cisplatin for 8 h, respectively, were fractionally centrifuged. Cytosolic and mitochondrial concentrations of cytochrome c were determined by ELISA as described in ‘Materials and methods’. As shown in Figure 5, incubation with chemotherapeutics induced cytochrome c release from mitochondria into the cytosol, thereby increasing the cytosolic concentration of cytochrome c from approximately 30 to 75%. No differences were observed between control and NCI H460-Akt1 cells, indicating that activated Akt1 did not prevent the release of cytochrome c from the mitochondria.

Caspase 9 may be phosphorylated and thereby inactivated by Akt upon phosphorylation at serine 198 (Cardone et al, 1998). However, we only observed very subtle differences in the caspase 9 phosphorylation (data not shown), making selective caspase 9 inactivation unlikely to be causative for Akt1-mediated chemoresistance.
DISCUSSION

PKB/Akt has been described as a central mediator of antiapoptotic signalling and as a mediator of reduced sensitivity of cancer cells towards chemotherapeutic agents (West et al, 2002). Recently, we could show that expression of constitutively active farnesylated Akt1 (CA-Akt) renders MCF10A mammary epithelial cells and A549 non-small-cell lung cancer (NSCLC) cells more resistant to the treatment with cell cycle independent chemotherapeutics such as cisplatin and Mitoxantrone (Schmidt et al, 2002). In this study, we examined the effects of CA-Akt expression in human NCI H460 NSCLC cells regarding chemosensitivity and the modulation of apoptotic pathways. Utilising an expression vector encoding Akt1 devoid of its PH domain and a C-terminally fusion of a farnesylation sequence described recently (Schmidt et al, 2002), we generated stable NCI H460 cell clones expressing CA-Akt. This constitutive activation of PKB/Akt resulted in a decreased sensitivity of NCI H460 cells towards a panel of chemotherapeutic agents currently used in the clinic (Table 1). It has to be noted that we observed the mediation of chemoresistance by CA-Akt primarily under conditions of low serum and to a far lesser extent in full growth medium. We explain this observation by the fact that constitutive activation of Akt1 interferes with the activation of defined apoptotic triggers.
Under these conditions, the activity of ectopically expressed CA-Akt may not provide a further survival advantage compared to active endogenous Akt alone. The most profound desensitisation was detected for Mitoxantrone, doxorubicin, and cisplatin (Figure 2). These agents can exert their cytotoxic mode of action by inducing DNA damage irrespective of the cell cycle phase. Mitoxantrone and doxorubicin have been described to intercalate with DNA at high concentrations, but also to inhibit Topoisomerase II, thereby leading to persistent double-strand breaks of DNA (Bodley et al., 1989; Boland et al., 2000). Cisplatin has been shown to alkylate DNA and to lead to the activation of caspase 8 with death receptors or the release of cytochrome c. Only very subtle differences in the caspase 9 phosphorylation, neither differences in the release of cytochrome c nor the expression of the ‘apoptosome’ associated protein Apaf-1 (data not shown) were detected between CA-Akt1 and control cells. This may suggest that the onset of p53 transactivation itself is delayed by the expression of CA-Akt. Moreover, expression of MDM2 and p53 declined after 36 h in NCI H460-Akt1 cells, but no decline was detected in control cells.

In summary, quantitative or kinetic differences were observed towards cell cycle specific drugs such as paclitaxel. Thus, we can exclude that the chemoresistance in NCI H460-Akt1 cells is simply due to the reduced growth rate of the transfectants. To further study the molecular mechanisms underlying the CA-Akt-mediated altered chemosensitivity, we analysed various apoptotic pathways. In summary, quantitative or kinetic differences were observed in the suppression or delay of molecular pathways of apoptosis induction, but no complete inhibition could be accounted to CA-Akt1. Different pathways for the induction of apoptosis have been discovered, for example, the activation of death receptors or the release of cytochrome c from the mitochondria. Both pathways comprise the activation of caspase cascades, leading to cell death. The proteolytic cascade consists of initiator caspases such as caspases 8, 9, and 10, and downstream effector caspases, for example, caspase 3 and 7 (Nunez et al., 1998). Akt1 has been described to suppress apoptotic stimuli by interfering with apoptotic pathways, for example, by phosphorylation of caspase 9 (Cardone et al., 1998) or the proapoptotic Bcl-2 homologue Bad (Datta et al., 1997). Analysing the activation of caspases upon stimulation with Mitoxantrone or cisplatin at concentrations and time points leading to DNA fragmentation in control cells but not in NCI H460-Akt1 cells exhibited a kinetic delay as well as quantitative, but not qualitative differences in the activation of the caspase cascade. Western Blot analysis revealed that upon treatment with cisplatin control cells showed cleavage of both initiator caspases 8 and 9 as well as the effector caspases 7 and 3 and the caspase 3/7 target protein PARP, while only caspase 8 was weakly activated in NCI H460-Akt1 cells at that time point (Figure 3A and B). These findings were supported by caspase activity assays showing a profound reduction in the activation of initiator caspases 8 and 9 as well as the effector caspase 3 in NCI H460-Akt1 cells compared to control cells upon treatment with cisplatin, while upon treatment with Mitoxantrone an altered activation was only observed in caspase 9 and 3 as caspase 8 is hardly activated by Mitoxantrone at all (Figure 3C).

The mitochondrial apoptosis pathway plays an important role in the execution of chemotherapy-induced apoptosis. Cytosolic cytochrome c binds to Apaf-1 and together with caspase 9 forms a complex termed ‘apoptosome’. Within the ‘apoptosome’, caspase 9 is proteolytically cleaved and activated (Cain et al., 2000). Yet, neither differences in the release of cytochrome c from mitochondria (Figure 5) nor the expression of the ‘apoptosome’ associated protein Apaf-1 (data not shown) were detected between CA-Akt1 and control cells upon treatment with cisplatin or Mitoxantrone. Only very subtle differences in the caspase 9 phosphorylation, which is known to be inactivated by Akt1 (Cardone et al., 1998), could be observed in NCI H460-Akt1 cells (data not shown), making selective caspase 9 inactivation unlikely to be causative for Akt1-mediated chemoresistance. Other proteins involved in mitochondrial membrane integrity are members of the Bcl-2 family. One potential mechanism by which Akt1 may interfere with proapoptotic members of this family is the inhibition of a Bax conformational change preventing disruption of mitochondrial inner membrane potential and caspase 3 activation (Yamaguchi and Wang, 2001). Analysis of the expression levels of Bcl-2 and Bcl-1 or the induction of Bax expression after exposure to Mitoxantrone or cisplatin did not reveal differences between NCI H460-Akt1 and control cells. In contrast, protein levels of antiapoptotic Bcl-xL were increased in NCI H460-Akt1 cells compared to control cells. Bcl-xL overexpression has been shown to protect cells from p53-mediated apoptosis (Schott et al., 1995). Thus, the induction of Bcl-xL overexpression might account for an Akt1-mediated antiapoptotic mechanism.

The p53 tumour-suppressor protein pathway also plays an important role in the transduction of proapoptotic signals towards various forms of cellular stress, such as DNA damage. Upon DNA damage, p53 is activated via phosphorylation by Chk1, Chk2, ATM, and ATR, and may translocate into the nucleus, where it induces the transcription of pro-apoptotic proteins such as Bax, as well as its antagonist MDM2 as a negative feedback loop (Sionov and Haupt, 1999). PKB/Akt has been shown to phosphorylate MDM2 at Ser 166 and Ser 186 (Mayo and Donner, 2001). After phosphorylation, MDM2 may likewise translocate from the cytoplasm into the nucleus, where it can block p53 transactivation and promote p53 degradation. Our results show an induction of p53 and successively MDM2 upon treatment with cisplatin (Figure 6). However, induction of MDM2 expression as a p53-regulated gene was delayed in CA-Akt-expressing cells compared to control cells. This may suggest that the onset of p53 transactivation itself is delayed by the expression of CA-Akt. Moreover, expression of MDM2 and p53 declined after 36 h in NCI H460-Akt1 cells, but no decline was detected in control cells.

In summary, our results show that ectopic expression of constitutively activated Akt1 in NCI H460 human NSCLC cells can cause partial resistance towards a class of chemotherapeutics and may increase the apoptotic threshold or delay time course of certain apoptotic pathways, but does not completely suppress the activity of specified caspases or the chemotherapeutic-induced apoptosis. It is interesting to note that chemoresistance is only conferred towards non-cell cycle-dependent chemotherapeutics primarily interfering with DNA. From this point of view, it will be worthwhile to study potential target proteins of Akt directly involved in the sensing of DNA damage such as Chk1 and 2, ATM, ATR, and other proteins involved in the DNA damage checkpoint pathway. Furthermore, our data support the notion that a pharmaceutical drug-inhibiting Akt activity may not be sufficient to kill cancer cells on its own, but may be used to lower the apoptotic threshold and to resensitise chemoresistant tumours in combination treatment with defined chemotherapeutic drugs.

ACKNOWLEDGEMENTS

We are grateful to Mrs Sylvia Finkenagel and Sabine Falk for excellent technical assistance. This work was supported by a grant from the Federal Ministry of Science, Research and Education (0311 334) to ASTA Medica.

REFERENCES

Alessi D, Cohen P (1998) Mechanism of activation of protein kinase B. Curr Opin Gen Dev 8: 55 – 62

Asada M, Yamada T, Ichiho H, Delia D, Miyazono K, Fukumuro K, Mizutani S (1999) Apoptosis inhibitory activity of cytoplasmic...
p21(Cip1/WAF1) in monocytic differentiation. EMBO J 18: 1223–1234
Bellaccosa A, de Feo D, Godwin AK, Bell DW, Cheng JQ, Altomare DA, Wan M, Duboeau L, Scambia G, Masullo V (1995) Molecular alterations of the Akt2 oncogene in ovarian and breast carcinomas. Int J Cancer 64: 280–285
Bodley A, Liu LF, Israel M, Seshadri R, Koseki Y, Giuliani FC, Kirschbaum S, Silber R, Potmesil M (1989) DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin conjugates with DNA. Cancer Res 49: 5969–5978
Boylan MP, Fitzgerald KA, O’Neill LAJ (2000) Topoisomerase II is required for mitoxantrone to signal nuclear factor kappa B activation in HL60 cells. J Biol Chem 275: 25231–25238
Brunet A, Bonni A, Zimonjic DJ, Luo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME (1999) Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell 96: 857–868
Cain K, Bratton SB, Langlais C, Walker G, Brown DG, Sun XM, Cohen GM (2000) Apaf-1 oligomersize into biologically active approximately 700-kDa and inactive approximately 1.4-MDa apoptosome complexes. J Biol Chem 275: 6607–6670
Campbell RA, Bhat-Nakshatri P, Constantindou D, Ali S, Nakshatri H (2001) PI3 kinase/Akt-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 276: 16877–16884
Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, Reed JS (1998) Regulation of cell death pathway caspase-9 by phosphorylation. Science 282: 1318–1321
Collado M, Medema RH, Garcia-Cao I, Dubuisson ML, Barradas M, Glassford J, Rivas C, Burgering BM, Serrano M, Lam EW (2000) Inhibition of the phosphoinositide 3-kinase pathway induces a senescence-like arrest mediated by p27Kip1. J Biol Chem 275: 21960–21969
Cross DA, Alessi DR, Cohen P, Andjelkovic M, Hemmings BA (1995) Inhibition of glycolc synthase kinase-3 by insulin mediated protein kinase B. Nature 378: 785–789
Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME (1997) Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231–241
Deprez J, Vertommen D, Alessi DR, Hue L, Rider MH (1997) Phosphorylation and activation of heart 6-phosphofructo-2-kinase by protein kinase B and other protein kinases of the insulin signaling cascades. J Biol Chem 272: 17269–17275
Dimmel S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeher AM (1999) Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399: 601–605
Ferreira CG, Span SW, Peters GJ, Kruyt FAE, Giaccone G (2000) Akt activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. J Biol Chem 275: 17382–17389
Hayakawa J, Ohmichi M, Kurachi H, Kanda Y, Hisamoto K, Nishio Y, Deprez J, Vertommen D, Alessi DR, Hue L, Rider MH (1997) Phosphorylation of GSK3 peptide and AMP-PNP. J Biol Chem 272: 17382–17389
Kaufmann SH, Earnshaw WC (2000) Induction of apoptosis by cancer chemotherapy. Cell 91: 231–241
Kraner S, Berlin M, Scambia G, Mascullio V (1995) Molecular alterations of the p53 gene in ovarian cancer cells to cisplatin. Cancer Res 55: 9588–9594
Liang J, Zubovitz R, Petrocchi T, Kotchetkov R, Conner MK, Han L, Lee JH, Giarallo S, Catzavelos C, Beniston R, Franssen ES, Slingerla JM (2002) PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 8: 1153–1160
Mayo LD, Donner DB (2001) A phosphatidylinositol 3-kinase/Akt pathway promotes trans-location of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA 98: 11598–11603
Mughe-Helmericks RC, Grimes HI, Bellacosa A, Malstrom SE, Tsichlis PN, Rosen N (1998) Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem 273: 29864–29872
Nunez G, Benedict MA, Hu Y, Inohara B (1998) Caspases: the proteases of the apoptotic pathway. Oncogene 17: 3237–3245
Obata T, Yaffe MB, Leparc GG, Piro ET, Maegawa H, Kashiwagi A, Kikkawa R, Cantley LC (2000) Peptide and protein ligand screening defines optimal substrate motifs for AKT/PKB. J Biol Chem 46: 36108–36115
Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB (1999) NFkB activation by tumour necrosis factor requires the Akt serine/threonine kinase. Nature 401: 82–85
Page C, Lin HJ, Jin Y, Castle VP, Nunez G, Huang M, Lin J (2000) Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Res 20: 407–416
Panka DJ, Mano T, Suhara T, Walsh K, Mier JM (2001) Phosphatidylinositol 3-kinase/Akt activity regulates c-FLIP expression in tumor cells. J Biol Chem 276: 6893–6896
Peter ME, Krammer PH (1998) Mechanisms of CD95 (APO-1/Fas)-mediated apoptosis. Curr Opin Immunol 10: 545–551
Pugazhenthi S, Nesterova A, Sable C, Heidenreich KA, Boxer ML, Heasley LE, Reusch JE (2000) Akt/protein kinase B up-regulates Bcl-2 expression through a CAM-response element-binding protein. J Biol Chem 275: 10761–10766
Ringel MD, Hayre MG, Saito N, Saunier B, Schuppert F, Burch H, Bernet V, Burman KD, Kohn LD, Saji M (2001) Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res 61: 6105–6111
Roy HK, Olusofa BF, Clemens DL, Karolski WJ, Ratashak A, Lynch HT, Smyrk TC (2002) AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis 23: 201–205
Scalia P, Heart E, Comai L, Vigneri R, Sung CK (2001) Regulation of the Akt/glycogen synthase kinase-3 axis by insulin-like growth factor-II via activation of the human insulin receptor isoform-A. J Cell Biochem 82: 610–618
Schmidt M, Hoevelmann S, Beckers TL (2002) A novel form of constitutively active farnesylated Akt prevents mammary epithelial cells from anoikis and suppresses chemotheraphy-induced apoptosis. Br Breast 87: 924–932
Schott AP, Alfie IP, Nunez G, Clarke MF (1995) Bcl-XYL protects cancer cells from p53-mediated apoptosis. Oncogene 11: 1589–1594
Sionon RV, Haupi Y (1999) The cellular response to p53: the decision between life and death. Oncogene 18: 6145–6157
Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP, Mak TW (1998) Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95: 29–39
West KA, Castillo SS, Dennis PA (2002) Activation of the PI3K/AKT pathway and chemotherapeutic resistance. Drug Resist Update 5: 234–248
Wymann MP, Zvelebil M, Laffargue M (2003) Phosphoinositide 3-kinase signaling – which way to target? Trends Pharm Sci 24: 366–376
Yamaguchi H, Wang HG (2001) The protein kinase PKB/Akt regulates cell survival and apoptosis by inhibiting Bax conformational change. Oncogene 20: 7779–7786
Yang J, Croun P, Good VM, Thompson V, Hemmings BA, Barford D (2002) Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3 peptide and AMP-PNP. Nat Struct Biol 9: 940–944
Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC (2001) Cytoplasmic AICD is a survival factor for the CD95 (APO-1/Fas) receptor. Mol Cell Biol 21: 42–49
Zou H, Li Y, Liu X, Wang X (1999) An APAF-1 cytochrome C Domain promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA 96: 11598–11603
Molecular and Cellular Pathology